PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pooled 5-FU Population PK Model Supports Lean Mass and Model-Informed Dosing

5-fluorouracilfluoropyrimidinescolorectal cancerpopulation pharmacokineticsmodel-informed precision dosingtherapeutic drug monitoringlean body massNONMEMIPD meta-analysisoncology Pharmacokinetics / TDM
Also in Oncology

Background Information

Leverage lean body mass for precise 5-FU dosing!

Understanding the pharmacokinetics of 5-fluorouracil is crucial for optimizing dose and therapeutic efficacy, especially in colorectal cancer treatment. A model-based approach using lean body mass and model-informed precision dosing improves target attainment significantly better than traditional TDM methods. The study suggests a shift towards lean body mass-based dosing and model-informed strategies, which could reduce variability seen with body-surface area dosing. Utilizing lean body mass and model-informed precision dosing can enhance therapeutic outcomes in 5-fluorouracil therapy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Briki M, Thoueille P, Joerger M, Chatelut E, Sterle M, Schmitt A, Wagner AD, Buclin T, Carrara S, Guidi M

Citation: Briki M, Thoueille P, Joerger M, et al. Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics. Cancer chemotherapy and pharmacology. 2026;96(1). doi:10.1007/s00280-026-04885-x

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.